Is the anatomical distribution of low-grade gliomas linked to regions of gliogenesis?

Anne Jarstein Skjulsvik1,2, Hans Kristian Bø3,4, Asgeir Store Jakola5,6,12, Erik Magnus Berntsen4,8, Lars Eirik Bø9, Ingerid Reinertsen9, Kristin Smistad Myrmel10, Kristin Åberg10, Thomas Berg10, Hong Yan Dai1, Roar Kloster11, Sverre Helge Torp1,2, Ole Solheim7,12

Abstract

Introduction   According to the stem cell theory, two neurogenic niches in the adult human brain may harbor cells that initiate the formation of gliomas: The larger subventricular zone (SVZ) and the subgranular zone (SGZ) in the hippocampus. We wanted to explore whether defining molecular markers in low-grade gliomas (LGG; WHO grade II) are related to distance to the neurogenic niches.

Methods   Patients treated at two Norwegian university hospitals with population-based referral were included. Eligible patients had histopathological verified supratentorial low-grade glioma. IDH mutational status and 1p19q co-deletion status was retrospectively assessed. 159 patients were included, and semi-automatic tumor segmentation was done from pre-treatment T2-weighted (T2W) or Fluid-Attenuated Inversion Recovery (FLAIR) images. 3D maps showing the anatomical distribution of the tumors were then created for each of the three molecular subtypes (IDH mutated/1p19q co-deleted, IDH mutated and IDH wild-type). Both distance from tumor center and tumor border to the neurogenic niches were recorded.

Results   In this population-based cohort of previously untreated low-grade gliomas, we found that low-grade gliomas are more often found closer to the SVZ than the SGZ, but IDH wild-type tumors are more often found near SGZ.

Conclusion   Our study suggests that the stem cell origin of IDH wild-type and IDH mutated low-grade gliomas may be different.

Keywords   Low-grade glioma · Subventricular zone · Subgranular zone · IDH mutation · 1p19q co-deletion · 3D brain map

Introduction

The origin of gliomas, and the question of whether all gliomas have a similar or even the same cellular origin, is much discussed. The long-reigning hypothesis that gliomas arise from fully differentiated glia has been largely abandoned and it is now widely believed that cancer stem cells contribute to gliomagenesis and treatment resistance [1–4].

Two niches in the adult human brain harbor neural stem cells (NSC) that ensures active neurogenesis and glial cell migration: the larger subventricular zone (SVZ) and the subgranular zone (SGZ) in the hippocampus [5]. Due to their shared genetic expression with tumor cells, capability of self-renewal and migratory potential the NSCs might be capable of transformation into cancer stem cells and initiate glioma formation [6–8]. Identifying a cell of origin is fundamental for understanding disease progression, and a recent study by Lee et al. speculated that astrocyte-like NSCs with low-level driver mutations (TERT, EGFR, PTEN and TP53) in the SVZ may be the cell of origin in glioblastomas [8].

A defining event in the development and progression of gliomas is the isocitrate dehydrogenase (IDH) mutation [9], which is present in 70% of low-grade gliomas [10]. It precedes 1p19q co-deletion, which is also considered an early event in gliomagenesis [11, 12]. In the recent WHO classification these two molecular markers now define the diffuse glioma subtypes with different prognoses. Oncogenic mutations in stem cells or progenitor cells might also affect cancer cell migration and several studies have reported that the mutational status is related to the anatomical distribution pattern of low-grade glioma (LGG) subtypes in the brain. We therefore hypothesized that the anatomical distribution...
of LGG molecular subtypes may relate to the neurogenic niches.

In this population-based study with data from two Norwegian university hospitals, we aimed to analyze the anatomical distribution of LGGs of WHO grade II in a three-dimensional (3D) standard Montreal Neurological Institute (MNI) space. We wanted to explore whether molecular subtype could be linked to distance from lesions to the two neurogenic niches in human adults, namely the subventricular zone and the subgranular zone.

Materials and methods

Patients

Eligible patients were adults (≥ 18 years) diagnosed with supratentorial LGG at St. Olavs University Hospital between 1998 and 2015 or at the University Hospital of North Norway between 1998 and 2009. The two university hospitals have region-based referral and together cover a geographical catchment region with 1.2 million inhabitants (Statistics Norway; https://www.ssb.no/en/). Both hospitals favored early histopathological diagnosis (diagnostic biopsy or surgical resection) in suspected LGGs. Diagnostic MRIs were retrieved, and tissue samples were revised and analyzed to assess IDH status and 1p19q status. Of a total of 205 patients, 66 patients were diagnosed at the University Hospital of North Norway while the remaining 139 patients were diagnosed at St. Olavs University Hospital. 39 patients were excluded as diagnostic MRIs were unavailable or incomplete, six patients were excluded due to the lack of tissue to perform retrospective molecular analyses and one patient was excluded due to a change in diagnosis after histopathological review. Our final sample included 159 LGGs (62 from the University Hospital of North Norway and 97 patients from St. Olavs University Hospital).

Radiology and image interpretation

A radiologist experienced with LGG assessment and segmentation (H.K.B.) performed semi-automatic tumor segmentation as previously described [13]. Segmentations were performed in the open source software 3D Slicer 4.4.0 (https://www.slicer.org), a software platform for quantitative imaging [14]. Images were acquired on 18 different MRI systems on 10 different locations with field strengths between 0.5 and 3.0 T (16 on 0.5 T, 4 on 1.0 T, 86 on 1.5 T and 53 on 3.0 T). Of the MRI examinations used for pre-operative tumor segmentation 122 were Fluid-Attenuated Inversion Recovery (FLAIR) images, 30 were T2-weighted images and seven were T1-weighted contrast enhanced images. 92 of the 159 acquisitions were 3D sequences with a slice thickness of 1.0–2.0 mm and no inter-slice gap. 67 of 159 acquisitions were two-dimensional (2D) sequences with slice-thickness of 2.5–6.5 mm and inter-slice gap of 0.25–2.0 mm. In-plane resolution was in the range 0.41–1.02 mm (mean 0.88 mm).

Image registration

The segmented MRI images were all registered to the standard MNI coordinate space, which is defined by the ICBM-152 brain template [15]. The registration pipeline, which was based on the Advanced Normalization Tools (ANTs) toolkit [16], has been described in detail in a previous paper [17]. The registrations were controlled manually, and in five cases they were corrected, either by modifying registration parameters (three cases) or by applying a manual, landmark-based registration (two cases). The registered segmentations were then summed voxel-wise to create maps of the tumor distribution.

Surfaces representing the SVZ were created manually based on the description given by Vescovi et al. [2] and the rendering of the lateral ventricles given in the Hammersmith atlas [18]. This atlas complies with the MNI space, and the distances from the registered tumors to the SVZ could thus be calculated directly.

The location of the SGZ was defined using the high-resolution atlas of the hippocampus and subfields created by the CoBrA Lab [19], which is available at https://cobra.ca/atlasses/Hippocampus-subfields/. The atlas was first registered to the MNI space, and the location of the SGZ was then defined as the center of mass of the dentate gyrus.

Molecular markers

The IDH mutational status and 1p19q co-deletion status were analyzed as previously described [20]. In summary, based on molecular markers patients were classified into three molecular groups: (i) the low-risk group being IDH mutated, 1p19q co-deleted, (ii) the intermediate-risk group being IDH mutated and 1p19q non-co-deleted, and (iii) the high-risk group being IDH wild-type [21]. These risk groups correspond to the WHO classification of (i) oligodendroglioma, IDH-mutant and 1p19q co-deleted, (ii) diffuse astrocytoma, IDH-mutant and (iii) diffuse astrocytoma, IDH wild-type.

Different diagnostic approaches were used at the two hospitals. For 62 patients the 1p19q co-deletion and IDH status were determined using multiplex ligation-dependent probe amplification (MLPA) directly since there was limited amount of tissue available. Samples classified as IDH wild-type after MLPA assessment were subject to PCR and DNA sequencing for IDH1 and IDH2 mutations. For 97 patients an integrated approach was used. Here, immunohistochemistry for IDH1 R132H and alpha thalassemia/mental retardation
syndrome X-linked (ATRX) protein expression was done as an initial step. If IDH R132H mutation and accompanying ATRX loss were observed, no further analyses were carried out and tumors were classified as IDH mutated, 1p19q non-co-deleted. Samples negative for IDH R132H mutation on immunohistochemistry were subject to PCR and DNA sequencing for other IDH1 and IDH2 mutations. In samples with IDH mutation and ATRX presence, we then carried out fluorescence in situ hybridization (FISH) to confirm the 1p19q codeletion. However, in three cases there was too little additional tissue available, and we had to assume 1p19q co-deletion based only IDH and ATRX presence without FISH confirmation. Also, for a selected group of IDH1 R132H-negative patients (n = 7) we were not able to do PCR and DNA sequencing for other IDH-mutations.

Statistics

Analyses were performed using IBM SPSS Statistics for Windows, Version 25.0. Statistical significance was set to p < 0.05. Q-Q plots were used to assess normal distribution in continuous data. Chi-squared tests were used for comparison analysis of categorical variables. Nonparametric Mann–Whitney U and Kruskall-Wallis test were used for comparison of continuous variables.

Ethics

The regional ethical committee of Central Norway approved this project (reference 2016/1377 and 2015/1460).

Results

The study included 159 previously untreated patients with LGG. 113 were IDH mutated, 46 were IDH wild-type, and 49 were both IDH mutated and 1p19q co-deleted (Fig. 1; Table 1). Based on tumors segmented in pretreatment MRI registered to MNI space, we measured the shortest distance from tumor border and tumor center to both neurogenic niches (Table 2). In 108 patients, the tumor involved SVZ and in 72 patients the tumor involved SGZ and the distance from tumor border to neurogenic niches was set to zero.

There were differences between the different molecular groups (IDH mutated/1p19q co-deleted vs IDH mutated vs IDH wild-type) when it came to the distance from SVZ to tumor, but only when measured from tumor center (p = 0.033, median distance 20.7 mm vs 16.5 mm vs 14.8 mm) and not from tumor border (p = 0.797, median distance was 0 mm for all groups) (Fig. 2a). There were also differences between molecular groups when it came to distance to the SGZ, both from tumor center (p < 0.001, median distance 42.3 mm vs 31.4 mm vs 20.8 mm) and from tumor border (p = 0.007, median distances 15.4 mm vs 3.8 mm vs 0 mm) (Fig. 2b).

Tumors with IDH mutation and 1p19q co-deletion showed similar distances from both SVZ and SGZ as the tumors with IDH mutation and no co-deletion. When analyzed for IDH mutation status alone (IDH mutated vs IDH wild-type) we found no differences when it came to distance to the SVZ from neither the tumor center (p = 0.055, median distance 18.7 mm vs 14.9 mm) nor tumor border (p = 0.752, median distance was 0 mm for both groups) (Fig. 2c). There were differences between the IDH mutated and IDH wild-type gliomas with respect to the SGZ, both when measured from tumor center (p < 0.001, median distance 35.7 mm vs 20.8 mm) and tumor border (p = 0.006, median distance 7.7 mm vs 0 mm) (Fig. 2d).

Frontal lobe location was prevalent among all LGGs with 53% (84 of 159 tumors) of tumors and among these 82% (69 of 84 tumors) were IDH mutated. Temporal lobe harbored 22% of all LGGs (35 of 159 tumors) and among these 43% were IDH wild-type (Table 3).

Discussion

In this population-based cohort of previously untreated low-grade gliomas, we found that LGGs are more often found closer to the SVZ than the SGZ. However, IDH wild-type tumors are more often found near the SGZ. These findings may suggest that the stem cell origin of IDH wild-type and IDH mutated LGGs may be different.

Previous studies on the distribution of molecular subtypes in gliomas have used a lobe-oriented approach that does not necessarily reflect the stem-cell theory of origin in gliomas [1]. Even so, it has been shown that LGGs in general are preferentially located near the insula [22] and are rarely found in the posterior regions of the brain [23, 24]. IDH-mutated gliomas are more often located in the frontal lobes, specifically around the rostral extension of the lateral ventricles [25–27], a location also seen in IDH-mutated glioblastomas [28, 29]. IDH wild-type tumors are more often located in diencephalon or brainstem [30]. We found that frontal location was more common with IDH-mutated tumors both with and without 1p19q codeletion, as previously shown [31, 32]. As the presence of 1p19q co-deleted tumors is limited to a subset of tumors with IDH mutations they show the same anatomical predilection as IDH-mutated tumors in general.

Only one previous study by Tejada Neyra et al. have looked at molecular markers in gliomas and their relation to neurogenic niches [27]. The exploratory study of Tejada Neyra et al. included 131 LGGs in addition to 237 glioblastomas and found the rostral extension of the lateral
ventricles to be a potential location for the cell of origin in IDH mutated gliomas [27]. Our study specifically looked at the positioning of tumors in relation to the neurogenic niches and confirmed the close relation to the ventricles in IDH mutated tumors. In addition, we identified a potential origin for IDH wild-type gliomas in the SGZ.

Recent evidence suggests that the SVZ may harbor the cell of origin in IDH wild-type glioblastomas [8] and thus proximity to this location might be expected for such gliomas. The SGZ and the SVZ differ in both anatomical location and histology; while the SVZ is close to the ventricles and the NSC of this niche give rise to both oligodendrocyte and neuronal lineages, the SGZ is tucked away in the hippocampus and their NSC give rise exclusively to the granular cells of dentate gyrus [33]. If the NSC is the cell of origin in all gliomas, this might explain our finding regarding the spatial relationship to the SGZ. However, the cell of origin is still debated, and another resident progenitor cell, the oligodendrocyte precursor cell (OPC), found in the SVZ and widely distributed in the cortex but not in SGZ, is also a possible cell of origin [34].

Several previous studies examining the anatomical location of LGGs were done before the 2016 revision of the WHO-classification system [26, 28, 30, 35–38] and results from these studies are not directly transferable to the current classification system of gliomas as some of them included oligoastrocytomas, a diagnosis that no longer exists [39]. This potential misclassification is unlikely as the material has been thoroughly reviewed as previously described [41] and the incidence of these tumors is even lower than for low-grade gliomas.

A possible confounder in our study is tumor volume, as a large tumor could show proximity to any region. However, IDH wild-type gliomas in our cohort were smaller than IDH mutated gliomas. Thus, tumor volume does not explain the short distance from the SGZ to IDH wild-type lesions. The frontal predilection of IDH mutated tumors may in part explain our findings as the distance to the SGZ is intrinsically longer for this group. But, as the SVZ has been suggested as potential location of origin for IDH wild-type tumors, this does not explain our findings regarding the SGZ.

A possible source of classification bias is the presence of other neuroglial tumors in our cohort. Tumors such as gangliogliomas or dysembryoplastic neuroepithelial tumors may be mistaken for diffuse WHO grade II LGG in small tissue samples. Both these WHO grade I tumors have a predilection for temporal lobe and do not carry an IDH mutation [39]. This potential misclassification is unlikely as the material has been thoroughly reviewed as previously described [41] and the incidence of these tumors is even lower than for low-grade gliomas.

A limitation of our study is the heterogeneity of the different sequences in MR protocols and variations in the interslice gap which may have influenced the accuracy of the segmentations. This is partly due to the retrospective nature of this study showing slightly differing tumor imaging protocols between the hospitals, but also the evolution of clinical brain tumor imaging going from 2D FLAIR to 3D FLAIR sequences.

Registration of a MR image with a tumor to a template based on healthy brains is associated with registration inaccuracies. This is more notable in tumors with a significant mass effect such as compression of the ventricles or midline shifts. Because of this, our Fig. 1 show some tumors to be located within the ventricles. Forcing the tumor outside the ventricle would impact the registration accuracy in other regions. We have therefore chosen to leave the tumors in the ventricles as this gives the most accurate impression of the actual tumor distribution.

The distribution of mutational status in our cohort is similar to what is published in other studies [42]. It should be acknowledged that diffuse WHO grade II LGGs is a heterogenous group and among the subgroup of IDH wild-type gliomas we find both “early glioblastomas”
and entities with a more benign course [43]. If we had sufficient tissue, a subclassification of IDH wild-type lesions including TERT promoter methylation, EGFR-amplifications or combined whole chromosome 7 gain and whole chromosome 10 loss (+ 7/− 10) could have been performed [44]. Also, whole-genome DNA methylation profiling of the whole cohort would have been of interest.

For this study, we used well-established molecular parameters in line with the current WHO classification of 2016 to determine complete IDH mutation status for almost all patients. For 1p19q codeletion status ATRX

| Table 1 Patient and tumor characteristics |
|------------------------------------------|
| **Patient characteristics** | No of patients (%) |
| Mean age at surgery (SD) | 46 (15) |
| Female gender (%) | 58 (37) |
| **Mutational status** | No of patients (%) |
| IDH mutated | 114 (72) |
| IDH wild-type | 45 (28) |
| 1p19q co-deleted | 50 (31) |
| **Molecular group** | No (%) |
| 1. Oligodendroglioma, IDH mutated, 1p19q co-deleted | 50 (31) |
| 2. Astrocytoma, IDH mutated, 1p19q non-co-deleted | 64 (40) |
| 3. Astrocytoma, IDH wild-type | 45 (28) |
| **Tumor volume** | Median (IQR) |
| Oligodendroglioma, IDH mutated, 1p19q co-deleted | 48.4 ml (78.9) |
| Astrocytoma, IDH mutated, 1p19q non-co-deleted | 73.4 ml (92.8) |
| Astrocytoma, IDH wild-type | 45.9 ml (115.3) |
| **Relation to neurogenic niches** | No (%) |
| Contact with SVZ | 108 (68) |
| Contact with SGZ | 72 (45) |
| Contact with both SVZ and SGZ | 70 (44) |
| No contact with either SVZ or SGZ | 48 (30) |

| Table 2 Median distance from neurogenic niches, both from border of tumor and center of tumor |
|------------------------------------------|
| WHO Diagnosis/risk group | Subventricular zone | Subgranular zone |
| | Median distance (Q1–Q3) | Median distance (Q1–Q3) |
| Border | Center | Border | Center |
| 1. Oligodendroglioma, IDH mutated, 1p19q co-deleted | 0 mm | 20.7 mm | 15.4 mm | 42.3 mm |
| (0–4.6) | (13.3–25.9) | (0–34.4) | (22.7–57.4) |
| 2. Astrocytoma, IDH mutated, 1p19q non-co-deleted | 0 mm | 16.5 mm | 3.8 mm | 31.4 mm |
| (0–4.3) | (12.0–23.7) | (0–22.4) | (15.1–52.0) |
| 3. Astrocytoma, IDH wild-type | 0 mm | 14.8 mm | 0 mm | 20.8 mm |
| (0–4.3) | (6.7–20.7) | (0–12.6) | (8.4–32.6) |
| **IDH mutation status** | | |
| IDH mutated | 0 mm | 18.7 mm | 7.7 mm | 35.7 mm |
| (0–4.5) | (12.3–24.5) | (0–29.9) | (18.5–56.0) |
| IDH wild-type | 0 mm | 14.9 mm | 0 mm | 20.8 mm |
| (0–4.3) | (6.7–20.7) | (0–12.6) | (8.4–32.6) |
immunohistochemistry was used as a surrogate marker in a subset of patients. Here, IDH mutant tumors with ATRX loss on immunohistochemistry was assumed to be 1p19q intact. Loss of ATRX expression is close to being mutually exclusive to 1p/19q codeletion [45], but this approach might have caused a slight underclassification of 1p19q co-deleted tumors. In addition, a small subset of tumors additional sequencing for other IDH-mutations than IDH1 R132H was not feasible. None of these patients were 1p19q co-deleted and were assumed to be IDH wild-type. Although non-IDH1 R132H mutations are rare, this may have influenced our findings.

The neurogenic niche may harbor potential cells of origin for glioma formation, but in addition the neurogenic niche itself is a system promoting proliferation and migration, and may therefore play a role in tumor cell migration, tumor maintenance and even recurrence [7]. It has therefore been speculated that glioma cells may migrate towards the neurogenic niches to take advantage of an already established system. This may also imply that the origin of gliomas lies elsewhere. Although our study is not equipped to answer this question, radiographic studies do show interesting patterns in glioma distribution related to the neurogenic niches: Glioblastomas with close contact to the SVZ are more likely to be multifocal and more invasive [46] and contact with the SVZ is a negative prognostic factor [47]. In contrast, contact with the SGZ does not seem to influence survival [48]. For low-grade astrocytoma, it has been reported that anatomical involvement of the SVZ might predict poor survival [49, 50]. Still, due to cell migration it is possible that the origin of gliomas is not related to the center of maximum tumor load.
In conclusion, our study confirms the close anatomical relationship between low grade gliomas and the SVZ, as found in previous studies. We found that IDH status predicts distance to the SGZ as the IDH wild-type tumors are more often found near SGZ. This may imply that IDH wild-type gliomas are of a different anatomical origin than IDH mutated gliomas.

Acknowledgments Open Access funding provided by NTNU Norwegian University of Science and Technology (incl St. Olavs Hospital - Trondheim University Hospital).

Funding LEB and IR have received funding from National Centre for Ultrasound and Image Guided Therapy, St.Olavs University Hospital, 7006 Trondheim, Norway. ASJ had funding through the Norwegian Cancer Society (#206187).

Compliance with ethical standards

Conflict of interest All the authors declared that they have no competing interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Sanai N, Alvarez-Buylla A, Berger MS (2005) Neural stem cells and the origin of gliomas. N Engl J Med 353(8):811–822. https://doi.org/10.1056/NEJMoa043666
2. Vescovi AL, Galli R, Reynolds BA (2006) Brain tumour stem cells. Nat Rev Cancer 6(6):425–436. https://doi.org/10.1038/nrc1889
3. Kreso A, Dick JE (2014) Evolution of the cancer stem cell model. Cell Stem Cell 14(3):275–291. https://doi.org/10.1016/j.stem.2014.02.006
4. Zong H, Parada LF, Baker SJ (2015) Cell of origin for malignant gliomas and its implication in therapeutic development. Cold Spring Harb Perspect Biol 7(5):a008334. https://doi.org/10.1101/cshperspect.a008334
5. Alvarez-Buylla A, Garcia-Verdugo JM, Tramontin AD (2001) A unified hypothesis on the lineage of neural stem cells. Nat Rev Neurosci 2(4):287–293. https://doi.org/10.1038/35067582
6. Modrek AS, Bayin NS, Placantonakis DG (2014) Brain stem cells as the cell of origin in glioma. World J Stem Cells 6(1):43–52. https://doi.org/10.4252/wjsc.v6.i1.43
7. Sinnaeve J, Mobley BC, Ihrle RA (2018) Space invaders: brain tumor exploitation of the stem cell niche. Am J Pathol 188(1):29–38. https://doi.org/10.1016/j.ajpath.2017.08.029
8. Lee JH, Lee JE, Kahng JY, Kim SH, Park JS, Yoon SJ, Um JY, Kim WK, Lee JK, Park J, Kim EH, Lee JH, Lee JH, Chung WS, Ju YS, Park SH, Chang JH, Kang SG, Lee JH (2018) Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature 560(7717):243–247. https://doi.org/10.1038/s41586-018-0389-3
9. Turkalp Z, Karamachandani J, Das S (2014) IDH mutation in glioma: new insights and promises for the future. JAMA Neurol 71(10):1319–1325. https://doi.org/10.1001/jamaneurol.2014.1205
10. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GI, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773. https://doi.org/10.1056/NEJMoa0808710
11. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174(4):1149–1153. https://doi.org/10.2353/ajpath.2009.080958
12. Cohen AL, Holmen SL, Colman H (2013) IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 13(5):345. https://doi.org/10.1007/s11910-013-0345-4
13. Bo HK, Solheim O, Jakola AS, Kvistad KA, Reinertsen I, Bernsen EM (2016) Intra-rater variability in low-grade glioma segmentation. J Neurooncol 131(2):393–402. https://doi.org/10.1007/s11060-016-2312-9
14. Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin JC, Pujol S, Bauer C, Jennings D, Fennesy F, Sonka M, Buatti J, Aylward S, Miller JV, Pieper S, Kikinis R (2012) 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging 30(9):1323–1341. https://doi.org/10.1016/j.mri.2012.05.001
15. Fonov V, Evans AC, Botteron K, Almli CR, McKinstry RC, Collins DL (2011) Unbiased average age-appropriate atlases for pediatric studies. NeuroImage 54(1):313–327. https://doi.org/10.1016/j.neuroimage.2010.07.033
16. Avants BB, Epstein CL, Grossman M, Gee JC (2008) Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal 12(1):26–41. https://doi.org/10.1016/j.media.2007.06.004
17. Sagberg LM, Iversen DH, Fyllingen EH, Jakola AS, Reinertsen I, Solheim O (2019) Brain atlas for assessing the impact of tumor location on perioperative quality of life in patients with high-grade glioma: A prospective population-based cohort study. NeuroImage Clin 21:101658. https://doi.org/10.1016/j.nicli.2019.101658
18. Hammers A, Allom R, Koepf MJ, Free SL, Myers R, Lemieux L, Mitchell TN, Brooks DJ, Duncan JS (2019) Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp 19(4):224–234. https://doi.org/10.1002/hbm.10123
19. Winterburn JL, Pruessner JC, Chavez S, Schira MM, Dobrin NJ, Voineskos AN, Chakravarty MM (2013) A novel in vivo atlas of human hippocampal subfields using high-resolution 3 T magnetice resonance imaging. NeuroImage 74:254–265. https://doi.org/10.1016/j.neuroimage.2013.02.003
20. Jakola AS, Skjulsvik AJ, Myr mel K, Sjavik K, Ugland G, Torp SH, Aaberg K, Berg T, Dai HY, Johnsen K, Kloorer R, Solheim O (2017) Surgical resection versus watchful waiting in low-grade
gliomas. Ann Oncol 28(8):1942–1948. https://doi.org/10.1093/annonc/mdx230

21. Cancer Genome Atlas Research N, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Nounmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman F, Hanners AE, Giannini C, Grillford M, Iavarone E, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O’Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vander Heiden VM, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallory D, Morris S, Paulskauski J, Penny R, Shelton T, Sherman M, Yen P, Black A, Bowen J, Dickostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tunnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carl森 S, Carter S, Chiu L, Chu A, Chua E, Cibulskis K, Clarke A, Coetzee SG, Dhalia N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Gu K, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferson SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglione DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PI, Parker JS, Persciu CM, Propotopopov A, Ren X, Roach J, Sabedot TS, Scheien J, Schumacher SE, Seidman JG, Seth S, Shen H, Simmons JS, Siphahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche TJ, Jr, Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Wu AX, Yang L, Zack TI, Zhang A, Aksyoy BA, Aracchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Hausdorfer D, Heiman DI, Ippe L, Jacobsen A, Ju Z, Katzman S, Kim H, Knijnenburg HJ, Dinjens WNM, Atmodimedjo PN, de Groot M, Kros JM, Lamszus K, Cloughesy T, Phillips HS (2011) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29(34):4482–4490. https://doi.org/10.1200/JCO.2010.33.8715

22. Parisot S, Darlix A, Baumann C, Zouaoui S, Yordanova Y, Blonski M, Rigau V, Chemouny S, Taillandier L, Bauchet L, Duffau H, Paragios N (2016) A probabilistic atlas of diffuse WHO grade II glioma locations in the brain. PLoS ONE 11(1):e0144200. https://doi.org/10.1371/journal.pone.0144200

23. Duffau H, Capelle L (2004) Preferential brain locations of low-grade gliomas. Cancer 100(12):2622–2626. https://doi.org/10.1002/cncr.20297

24. Chang EF, Clark A, Smith JS, Polley MY, Chang SM, Barbaro NM, Parsa AT, McDermott MW, Berger MS (2011) Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. J Neurosurg 114(3):566–573. https://doi.org/10.3171/2010.6.JNS091246

25. Yu J, Shi Z, Ji C, Lian Y, Yang W, Chen L, Mao Y (2017) Anatomical location differences between mutated and wild-type isocitrate dehydrogenase 1 in low-grade gliomas. Int J Neurosci 127(10):873–880. https://doi.org/10.1080/00207454.2016.1270278

26. Wang Y, Zhang T, Li S, Fan X, Ma J, Wang L, Jiang T (2014) Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas. Eur J Neurol 22(2):348–354. https://doi.org/10.1111/ene.12578

27. Tejada Neyra MA, Neuberger U, Reinhardt A, Brugnara C, Bonekamp D, Sill M, Wick A, Jones DTW, Radbruch A, Unterberg A, Debus J, Heiland S, Schlemmer HP, Herold-Mende C, Pfister S, von Deimling A, Wick W, Capper D, Bendzus M, Kickingereder P (2018) Voxel-wise radiographic mapping of tumor location with key molecular alterations in patients with glioma. Neuro-Oncology 20(11):1517–1524. https://doi.org/10.1093/neuonc/noy134

28. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, Yong WH, Seshagiri S, Modravan Z, Jiang Z, Aldape KD, Mischel PS, Laiu LM, Escovedo CJ, Chen W, Nghiembphu PL, James CD, Prados MD, Westphal M, Lansmus K, Cloughesey T, Phillips HS (2011) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29(34):4482–4490. https://doi.org/10.1200/JCO.2010.33.8715

29. Ellingson BM, Lai A, Harris RJ, Selfridge JM, Yong WH, Das K, Pope WB, Nghiembphu PL, Vinters HV, Laiu LM, Mischel PS, Cloughesey TF (2013) Probabilistic radiographic atlas of glioblastoma phenotypes. AJNR Am J Neuroradiol 34(3):533–540. https://doi.org/10.3174/ajnr.A3253

30. Qi S, Yu L, Li H, Ou Y, Qiu X, Ding Y, Han H, Zhang X (2014) Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett 7(6):1895–1902. https://doi.org/10.3892/ol.2014.1048

31. Wijnenga MMJ, van der Voort SR, French PJ, Klein S, Dubbink HJ, Dijnens WNM, Atmodimedjo PN, de Groot M, Kros JM, Schouten JW, Dirven CMF, Vincent AJPE, Smits M, van den Bent MJ (2019) Differences in spatial distribution between WHO 2016 low-grade glioma molecular subgroups. Neuro-Oncology Adv. 1(1):001. https://doi.org/10.1093/noan/vdz001

32. Darlix A, Deverdun J, Menjet de Champfleur N, Castan F, Zouaoui S, Rigau V, Fabbro M, Yordanova Y, Le Bars E, Bauchet L, Goze C, Duffau H (2017) IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas. J Neurooncol 133(1):37–45. https://doi.org/10.1007/s11063-017-2421-0

33. Obernier K, Alvarez-Buylia A (2019) Neural stem cells: origin, heterogeneity and regulation in the adult mammalian brain. Development 146(4):158059. https://doi.org/10.1242/dev.158059

34. Kondo T, Raff M (2000) Oligodendrocyte precursor cells reprogrammed to become multipotential CNS stem cells. Science 289(5485):1754–1757

35. Ren X, Cui X, Jiang Z, Sui D, Li J, Wang Z (2012) Co-deletion of chromosome 1p19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients. PLoS ONE 7(3):e32764. https://doi.org/10.1371/journal.pone.0032764

36. Duffau H, Capelle L (2004) Preferential brain locations of low-grade gliomas. Cancer 100(12):2622–2626. https://doi.org/10.1002/cncr.20297

37. Chang EF, Clark A, Smith JS, Polley MY, Chang SM, Barbaro NM, Parsa AT, McDermott MW, Berger MS (2011) Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. J Neurosurg 114(3):566–573. https://doi.org/10.3171/2010.6.JNS091246
36. Metellus P, Coulibaly B, Colin C, de Paula AM, Vasiljevic A, Taieb D, Barlier A, Boisselier B, Mokhtari K, Wang XW, Loun-dou A, Chapon F, Pineau S, Ouafik L, Chinot O, Figarella-Branger D (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120(6):719–729. https://doi.org/10.1007/s00401-010-0777-8

37. Laigle-Donadey F, Martin-Duverneuil N, Lejeune J, Cриниe E, Capelle L, Duffau H, Cornu P, Broet P, Kujas M, Mokhtari K, Carpentier A, Sanson M, Hoang-Xuan K, Thillet J, Delattre JY (2004) Correlations between molecular profile and radiologic pattern in oligodendrogliomas. Neurology 63(12):2360–2362

38. Fellah S, Caudal D, De Paula AM, Dory-Lautrec P, Figarella-Branger D, Chinot O, Metellus P, Cozzozen PI, Confort-Gouny S, Ghattas B, Callot V, Girard N (2013) Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? AJNR Am J Neuroradiol 34(7):1326–1333. https://doi.org/10.3174/ajnr.A3352

39. Cavenee WK, Louis DN, Ohgaki H, Wiestler OD, International Agency for Research on Cancer (2016) WHO classification of tumours of the central nervous system. World Health Organization classification of tumours, Revised, 4th edn. International Agency For Research on Cancer, Lyon

40. Eismaelit L, Stensjoen AL, Berntsen EM, Solheim O, Reinerksen I (2018) The direction of tumour growth in glioblastoma patients. Sci Rep 8(1):1199. https://doi.org/10.1038/s41598-018-19420-z

41. Jakola AS, Myrmel KS, Kloster R, Torp SH, Lindal S, Unsgard G, Solheim O (2012) Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA 308(18):1881–1888. https://doi.org/10.1001/jama.2012.12807

42. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians J, Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendrogial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118(4):469–474. https://doi.org/10.1007/s00401-009-0561-9

43. Albaidula A, Chan AK, Shi Z, Li Y, Zhang R, Yang R, Li KK, Chung NY, Yao Y, Zhou L, Wu J, Chen H, Ng HK (2017) Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro-Oncology 19(10):1327–1337. https://doi.org/10.1093/neurono/nox078

44. Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, Kleinschmidt-DeMasters BK, Perry A, Reifenberger G, Stupp R, von Deimling A, Weller M (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". Acta Neuropathol 136(5):805–810. https://doi.org/10.1007/s00401-018-1913-0

45. Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt V, Mittel-bronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A (2015) ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropatholog 129(1):133–146. https://doi.org/10.1007/s00401-014-1370-3

46. Lim DA, Cha S, Mayo MC, Chen MH, Keles E, VandenBerg S, Berger MS (2007) Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro-Oncology 9(4):424–429. https://doi.org/10.1215/15228157-2007-023

47. Jafri NF, Clarke JL, Weinberg V, Barani U, Cha S (2013) Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. Neuro-Oncology 15(1):91–96. https://doi.org/10.1093/neurono/nss268

48. Mistry AM, Dewan MC, White-Dzuro GA, Brinson PR, Weaver KD, Thompson RC, Ihrie RA, Chambless LB (2017) Decreased survival in glioblastomas is specific to contact with the ventricular-subventricular zone, not subgranular zone or corpus callosum. J Neurooncol 132(2):341–349. https://doi.org/10.1007/s11063-017-2374-3

49. Wen B, Fu F, Hu L, Cai Q, Xie J (2018) Subventricular zone predicts high velocity of tumor expansion and poor clinical outcome in patients with low grade astrocytoma. Clin Neurol Neurosurg 168:12–17. https://doi.org/10.1016/j.clineuro.2018.02.036

50. Liu S, Wang Y, Fan X, Ma J, Ma W, Wang R, Jiang T (2016) Anatomical involvement of the subventricular zone predicts poor survival outcome in low-grade astrocytomas. PLoS ONE 11(4):e0154539. https://doi.org/10.1371/journal.pone.0154539

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Affiliations

Anne Jarstein Skjulsvik1,2,• · Hans Kristian Bø3,4 · Asgeir Store Jakola5,6,12 · Erik Magnus Berntsen4,8 · Lars Eirik Bø9 · Ingerid Reinertsen9 · Kristin Smidstad Myrme10 · Kristin Sjävik11 · Kristin Åberg10 · Thomas Berg10 · Hong Yan Dai1 · Roar Kloster11 · Sverre Helge Torp1,2 · Ole Solheim7,12

Hans Kristian Bø
hanskrb@gmail.com

Asgeir Store Jakola
legepost@gmail.com

Erik Magnus Berntsen
erik.berntsen@ntnu.no

Lars Eirik Bø
lars.eirik.bo@sintef.no

Ingerid Reinertsen
ingerid.reinertsen@sintef.no

Kristin Smidstad Myrme
Kristin.smidstad.myrme@unn.no

Kristin Sjävik
Kristin.Sjavik@unn.no

Kristin Åberg
christin.aaberg@unn.no

Thomas Berg
thomas.berg@unn.no

Hong Yan Dai
hong.yan.dai@stolav.no

• Corresponding author.
Roar Kloster
roar.kloster@unn.no

Sverre Helge Torp
Sverre.torp@ntnu.no

Ole Solheim
ole.solheim@ntnu.no

1 Department of Pathology, St. Olavs University Hospital, Trondheim, Norway
2 Departments of Clinical and Molecular Medicine, Faculty of Medicine, NTNU, Norwegian University of Science and Technology, 7491 Trondheim, Norway
3 Department of Diagnostic Imaging, Nordland Hospital Trust, Bodø, Norway
4 Department of Circulation and Medical Imaging, Faculty of Medicine, NTNU, Norwegian University of Science and Technology, 7491 Trondheim, Norway
5 Department of Neurosurgery, Sahlgrenska University Hospital, Gothenburg, Sweden
6 Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg, Sweden
7 Department of Neurosurgery, St. Olavs University Hospital, Olav Kyrres Gate, 7006 Trondheim, Norway
8 Department of Radiology and Nuclear Medicine, St. Olavs University Hospital, Olav Kyrres Gate, 7006 Trondheim, Norway
9 Department of Health Research, SINTEF Digital, Trondheim, Norway
10 Department of Clinical Pathology, University Hospital of North Norway, Tromsø, Norway
11 Department of Neurosurgery, University Hospital of North Norway, Tromsø, Norway
12 Department of Neuroscience and Movement Medicine, Faculty of Medicine, NTNU, Norwegian University of Science and Technology, 7491 Trondheim, Norway